New Study Suggests 2 Gene-Based Subtypes of Polycystic Ovarian Syndrome
http://www.scientificanimations.com / CC BY-SA (https://creativecommons.org/licenses/by-sa/4.0)

New Study Suggests 2 Gene-Based Subtypes of Polycystic Ovarian Syndrome

An NIH news release shared that a study on polycystic ovarian syndrome (polycystic ovary syndrome or PCOS) discovered that the condition might have two distinct subtypes based on genetic mutations. Through…

Continue Reading New Study Suggests 2 Gene-Based Subtypes of Polycystic Ovarian Syndrome

Botox is on Its Way to Become a New Therapeutic Option for Children with Neurogenic Detrusor Overactivity

Botox Botox was first approved as a treatment for strabismus and blepharospasm, rare eye conditions, in 1989. Now, it is approved for 11 different conditions including cervical dystonia, chronic migraines,…

Continue Reading Botox is on Its Way to Become a New Therapeutic Option for Children with Neurogenic Detrusor Overactivity
A New Partnership will Advance Exosome-Based Gene Therapy for Neuromuscular Diseases
source: pixabay.com

A New Partnership will Advance Exosome-Based Gene Therapy for Neuromuscular Diseases

By engineering exosomes, Sarepta Therapeutics believes they can utilize gene therapies, RNA therapies, and gene editing without triggering an immune response in the body. They have just announced a new…

Continue Reading A New Partnership will Advance Exosome-Based Gene Therapy for Neuromuscular Diseases

Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease

A team of researchers recently evaluated a new biomarker in interstitial lung disease to see whether or not it could predict disease severity and ultimately mortality. The Biomarker Surfactant protein…

Continue Reading Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease
FDA Approves CRYSVITA for Tumor-Induced Osteomalacia
source: pixabay.com

FDA Approves CRYSVITA for Tumor-Induced Osteomalacia

Ultragenyx Pharmaceutical's therapy, CRYSVITA, has recently been approved by the FDA for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors. This approval comes after…

Continue Reading FDA Approves CRYSVITA for Tumor-Induced Osteomalacia